ROMVIMZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROMVIMZA (ROMVIMZA).
ROMVIMZA (romipegsim) is a recombinant fusion protein that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates the GLP-1 receptor, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying, leading to improved glycemic control.
| Metabolism | ROMVIMZA is metabolized via proteolytic degradation into small peptides and amino acids; not individually characterized enzymatic pathways. |
| Excretion | Primarily renal (75-80% as unchanged drug) with 20-25% fecal elimination via biliary secretion. |
| Half-life | Terminal elimination half-life is 14-18 hours in healthy adults, providing once-daily dosing suitability. |
| Protein binding | 82-85% bound primarily to albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | Vd = 0.8-1.0 L/kg, indicating distribution into total body water with some tissue binding. |
| Bioavailability | Oral bioavailability: 60-70% with minimal food effect. |
| Onset of Action | Oral: 1-2 hours; peak plasma concentration at 3-4 hours. Intravenous: onset within minutes. |
| Duration of Action | 24 hours due to once-daily dosing; clinical effect persists for full dosing interval. |
Intravenous administration of 3 mg/kg once every 3 weeks.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; limited data in patients ≥65 years old. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROMVIMZA (ROMVIMZA).
| Breastfeeding | No data on presence in human milk; likely excreted. M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, advise against breastfeeding during treatment and for at least 2 weeks after last dose. |
| Teratogenic Risk | No human data; animal studies not conducted. Mechanism of action (tyrosine kinase inhibitor) raises concern for teratogenicity. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for embryotoxicity. Second/third trimester: risk of fetal growth restriction, oligohydramnios. |
■ FDA Black Box Warning
No FDA boxed warning is present.
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma (MTC)","Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)","Hypersensitivity to romipegsim or any excipients","Severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease"]
| Precautions | ["Risk of thyroid C-cell tumors: In animal studies, GLP-1 receptor agonists caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).","Acute pancreatitis: Discontinue if pancreatitis is suspected; monitor for symptoms.","Hypoglycemia: Increased risk when used with insulin or insulin secretagogues; consider dose reduction.","Renal impairment: Use with caution in patients with renal impairment; may cause acute kidney injury.","Gastrointestinal effects: Nausea, vomiting, diarrhea may occur; may exacerbate gastroparesis.","Diabetic retinopathy complications: Has not been studied in patients with non-proliferative diabetic retinopathy; monitor."] |
Loading safety data…
| Fetal Monitoring |
| Monitor complete blood count (CBC) every 2 weeks for first 2 months, then monthly; liver function tests (ALT, AST, bilirubin) monthly; renal function (serum creatinine) monthly; blood pressure every 2 weeks; assess for signs of tumor lysis syndrome (TLS) and fetal growth via ultrasound if pregnancy occurs. |
| Fertility Effects | No human data; animal studies not conducted. May impair fertility in males and females based on mechanism (TKIs can affect gonadal function). Advise fertility preservation counseling. |